Dapagliflozin shows efficacy in glucose, weight control

A study of more than 800 type 2 diabetes patients revealed those who used dapagliflozin as an add-on to insulin and other diabetes medicines lost more weight and reduced insulin use compared with those who took a placebo. The findings appear in the Annals of Internal Medicine.

View Full Article in:

Los Angeles Times (tiered subscription model) · HealthDay News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ